Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HP 802247

Next Previous
X
Search
Drug Profile

HP 802247

Alternative Names: Allogeneic human skin replacement - Smith & Nephew Biotherapeutics; Allox™; DFB Healthpoint allogeneic human skin replacement; HP-802247; Human skin replacement - Smith & Nephew Biotherapeutics

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Healthpoint
  • Developer Smith & Nephew Biotherapeutics
  • Class Cell therapies; Skin disorder therapies
  • Mechanism of Action Fibrinogen replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Leg ulcer; Wounds

Most Recent Events

  • 23 Feb 2015 Smith & Nephew terminate a phase III trial in Leg ulcer in Czech Republic, Poland, Hungary, Belgium and Germany due to the outcome of previous study (NCT01853384)
  • 16 Jan 2015 Smith & Nephew terminates phase II trial in Leg ulcer in USA (NCT02154087)
  • 01 Dec 2014 Healthpoint completes a phase III trial for Leg ulcer in USA and Canada (NCT01656889)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top